天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >API>Digestive system drugs>Cetilistat
Cetilistat
  • Cetilistat
  • Cetilistat

Cetilistat

Price $783.2326
Package 1Kg/Bag
Min. Order: 1Kg/Bag
Supply Ability: 1-10 tons
Update Time: 2021-11-02

Product Details

Product Name: Cetilistat CAS No.: 282526-98-1
Min. Order: 1Kg/Bag Purity: 99%
Supply Ability: 1-10 tons Release date: 2021/11/02

Cetilistat (ATL-962) is a novel gastrointestinal lipase inhibitor developed by Alizyme in the United Kingdom and subsequently licensed worldwide by "Norgina BV". Sinrisat is undergoing phase 3 clinical trials in the United States. In Japan, shinlistat was approved as a treatment for obesity in September 2013 in collaboration with Takeda Pharmaceutical co. The product is called "Oblean".

Xinli company he is a long-term and strong specificity gastrointestinal lipase inhibitor, it through the stomach and small lumen inside the stomach lipase and the activity of pancreatic lipase serine parts forming covalent bonds make enzyme inactivation and play a role of treatment, the deactivation of the enzyme in the food can not be mainly triglyceride hydrolysis of fats to absorbable free fatty acids and single acylglycerol. Undigested triglycerides are not absorbed by the body, leading to reduced calorie intake and weight control. The major advantages of cetilistat are that it does not affect the activities of other enzymes in the gastrointestinal tract, does not suppress appetite, does not require dietary restriction, does not act on the nervous system, and is not absorbed, i.e. does not enter the bloodstream. After cetilistat is administered, the phenomenon of oily defecation (floating oil droplets on water surface) can occur 24 hours after cetilistat is administered, that is, the elimination of undigested fat.

According to statistical analysis by the Organization for Economic Cooperation and Development (OECD), the number of obese adults in the world's seven major pharmaceutical markets was about 125 million in 2008. On this trend, the number of obese adults in the market will reach 143 million by 2018. Suppose only a fraction of these obese people get treatment. It will increase the market value of the world's seven largest markets from $9 billion to $11 billion between 2008 and 2018. It can be seen that the market prospect of New Listat is very considerable.




Company Profile Introduction

You may like

Recommended supplier

Product name Price   Suppliers Update time
$29.00/200mg
VIP5Y
TargetMol Chemicals Inc.
2024-11-19
$0.00/1g
VIP1Y
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
2024-11-04
$1.00/25KG
VIP6Y
Hebei Weibang Biotechnology Co., Ltd
2024-10-28
$10.50/1KG
VIP4Y
Hebei Chuanghai Biotechnology Co,.LTD
2024-08-22
$10.00/1kg
VIP1Y
Hebei Zhuanglai Chemical Trading Co.,Ltd
2024-05-24
$0.00/1kg
VIP1Y
Shaanxi TNJONE Pharmaceutical Co., Ltd
2024-05-06
$15.00/1kg
Ouhuang Engineering Materials (Hubei) Co., Ltd
2024-04-26
$10.00/1kg
VIP1Y
Wuhan Xinhao Biotechnology Co., Ltd
2024-03-08
$25.00/1kg
VIP1Y
Sigma Audley
2024-02-22
$200.00/1KG
VIP2Y
Henan Fengda Chemical Co., Ltd
2024-01-02
INQUIRY
王亞潔
15638587096
wa15638587096@163.com